5/14/2008 | SS | Takeda completes subsequent offer for Millennium; merger set to close Wednesday
|
5/9/2008 | SS | Takeda completes tender offer for Millennium Pharmaceuticals; subsequent offer to end May 13
|
4/29/2008 | SS | Takeda, Millennium merger clears waiting period hurdle
|
4/11/2008 | SS | Takeda begins $25-per-share tender offer for Millennium
|
4/10/2008 | SS | Takeda to boost presence in oncology market with acquisition of Millennium Pharmaceuticals
|
4/10/2008 | CV | Market Commentary: Endo jumps on debut; takeout news lifts Millenium, other biotechs gain; NatCity in play
|
4/10/2008 | SS | Market Commentary: Views on Microsoft-Yahoo! diverge as News Corp., Google, AOL weigh in; Takeda to buy Millennium
|
12/10/2007 | CV | Market Commentary: WaMu bringing big deal; A&P watching P's & Q's; Millennium up on drug tests; MGI up on merger
|
11/2/2007 | CV | Market Commentary: Synaptics, Cray, Millennium up on earnings; Itron gutted; new issues open flat; Vanda doesn't open at all
|
8/28/2007 | CV | Market Commentary: PolyMedica convertibles skyrocket on takeover; AmeriCredit, Medtronic, slide; perfect storm slows volume
|
11/15/2006 | BTCV | Millennium greenshoe exercised in full, upping convertibles offer to $250 million
|
11/10/2006 | CV | Market Commentary: General Cable, upsized Millennium climb on trading debuts; Medis locked up; Disney slides on results
|
11/10/2006 | BTCV | New Issue: Millennium prices upsized $225 million five-year convertibles at 2.25%, up 37.5%
|
11/10/2006 | BT | Millennium stays at neutral from Merrill
|
11/9/2006 | BT | Market Commentary: Thermage, ActivBiotics IPOs on tap at lower ranges; Millennium, Elan market bonds; Vasogen off
|
11/9/2006 | CV | Market Commentary: SanDisk higher on rumors; Amkor jumps following results; General Cable up, Millennium silent in gray
|
11/9/2006 | BTCV | Millennium prices upsized $225 million five-year convertibles to yield 2.25%, up 37.5%
|
11/2/2006 | BT | Millennium says next major growth opportunity for Velcade is in front-line setting
|
11/2/2006 | BT | Millennium at neutral by Merrill
|
10/27/2006 | BT | Millennium kept at market perform by JMP
|
10/27/2006 | BT | Millennium still at neutral by Merrill
|
10/27/2006 | BT | Market Commentary: Genzyme slides on deal buzz; Cadence, Achillion up; Aspreva falls; Vertex gains 18%; Critical off on PIPE
|
10/26/2006 | BT | Millennium to reduce discovery technologies, related staff
|
10/26/2006 | BT | Market Commentary: Achillion gains on debut; Cadence slips; DOV Pharma nosedives; Celgene better; Renovis falls 76%
|
10/25/2006 | BT | Millennium gets neutral from Merrill
|
10/17/2006 | BT | Millennium raised to market perform by JMP
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/12/2006 | BT | Market Commentary: Genzyme gets AnorMED nod but hurt by 3Q; Nabi up 6% on asset sale; Trimeris off 13% on warning
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
10/10/2006 | BT | Millennium kept at neutral by Merrill
|
10/10/2006 | BT | Market Commentary: AnorMED gains 5% as Genzyme bests Millennium bid; DOV sinks 9% on hiring HSBC, up after close
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/27/2006 | BT | Millennium cut to market underperform by JMP
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
9/26/2006 | BT | AnorMED zooms after picking Millennium bid over Genzyme, but still seen firmly in play
|
9/26/2006 | BT | Millennium kept at neutral by Merrill
|
9/26/2006 | BT | Market Commentary: AnorMED rockets on Millennium bid but still seen in play; Genzyme mum; Indevus slips on trial's end
|
9/18/2006 | BT | Millennium gets neutral from Merrill
|
8/30/2006 | BT | Millennium tests MLN0415 in inflammatory disorder trial
|
8/9/2006 | BT | Millennium's Velcade gets FDA priority review
|
7/28/2006 | BT | Millennium kept at market perform by JMP
|
7/28/2006 | BT | Merrill maintains Millennium at neutral
|
7/27/2006 | BT | Millennium Pharmaceuticals second-quarter net income up to $3.9 million
|
6/22/2006 | BT | Millennium kept at neutral by Merrill
|
6/21/2006 | BT | Millennium study shows Velcade-based combination treatment superior to monotherapy in myeloma
|
6/15/2006 | BT | Millennium: no sale of company planned, will focus on pipeline product and growth
|
6/13/2006 | BT | Millennium says use as first treatment is key to Velcade's growth
|
6/9/2006 | BT | Millennium files supplemental NDA for Velcade injection
|
6/9/2006 | BT | Millennium kept at neutral by Merrill
|
6/9/2006 | BT | Market Commentary: Pozen plunges after FDA setback; NxStage climbs after follow-on; BioNumerik nixes IPO plans
|
6/5/2006 | BT | Merrill keeps Millennium at neutral
|
6/5/2006 | BT | Millennium's Velcade data shows improved survival in advanced lung cancer
|
6/5/2006 | BT | Millennium's Velcade injection shows 40% response rate in multiple myeloma patients
|
5/31/2006 | BT | Millennium's MLN1202 meets primary endpoint in atherosclerosis study
|
5/31/2006 | BT | Merrill neutral on Millennium's MLN1202
|
4/28/2006 | BT | Millennium maintained at market perform by JMP
|
4/28/2006 | BT | Merrill keeps Millennium at neutral
|
4/27/2006 | BT | Millennium achieves first-quarter 2006 non-GAAP profitability
|
4/18/2006 | BT | Millennium to start phase 3 trial of Velcade, rituximab combination for treatment of lymphoma
|
4/6/2006 | BT | Millennium, Crucell sign agreement for production of monoclonal antibodies
|
3/30/2006 | BT | ImmunoGen, Millennium extend agreement for tumor-activated prodrug
|
3/9/2006 | BT | Millennium receives $10 million milestone payment for Velcade sales
|
3/7/2006 | BT | Merrill keeps Millennium at neutral
|
3/6/2006 | BT | Millennium, Johnson & Johnson Pharmaceutical start Velcade trial for lung cancer
|
1/27/2006 | BT | Millennium kept at neutral by Merrill
|
1/27/2006 | BT | Millennium reiterated at market outperform by JMP
|
1/26/2006 | BT | Millennium's 2005 revenues up, loss per share shrinks to $0.64
|
1/6/2006 | BT | Millennium maintained by Merrill Lynch at neutral
|
1/6/2006 | BT | Market Commentary: Affymetrix lower, Millennium up on guidance; amid rotation into small caps Amgen, Genentech slide
|
12/13/2005 | BT | Millennium says Velcade studies show up to 92% response rates in multiple myeloma
|
12/12/2005 | BT | Millennium, Johnson & Johnson plan additional studies in response to Velcade results
|
11/3/2005 | BT | Millennium begins phase-1 trial of MLN8054 for treatment of advanced solid tumors
|
10/31/2005 | BT | JMP reiterates Millennium at market perform
|
10/28/2005 | BT | Thomas Weisel maintains Millennium at peer perform
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/27/2005 | BT | Merrill maintains Millennium at neutral
|
7/29/2005 | BT | Millennium kept by Merrill at neutral
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/25/2005 | BT | Millennium kept by Merrill at neutral
|
7/25/2005 | BT | Millennium kept by JMP at market perform
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
5/17/2004 | CV | Market Commentary: Protein Design Labs plunges, Millennium set to rise on drug results; Thoratec, Tower deals emerge
|
4/29/2003 | CV | Millennium Pharmaceuticals says $577.8 million convertibles tendered
|
4/21/2003 | CV | Market Commentary: Market still in thin, holiday mode; deal flow seen picking up swiftly
|
4/21/2003 | CV | Cendant buys back $852 million convertibles
|
4/14/2003 | CV | Merrill sees Millennium offering sweetener for 4.5% and 5% converts in 8%-13.5% yield to put range
|
3/31/2003 | CV | Millennium may add sweetener to discourage exercise of upcoming put
|
7/15/2002 | CV | Market Commentary: Converts close higher despite wild swing in stock markets
|
5/8/2002 | CV | Moody's cuts Corning to Baa3
|
4/29/2002 | CV | Millennium says $40,000 out of $600 million old COR Therapeutics notes tendered
|
4/23/2002 | CV | Market Commentary: New issues invigorate otherwise languid market; Calpine seen heading south
|
4/23/2002 | CV | Deutsche analysts suggest switching out of the COR 5% into 4.5%
|
4/22/2002 | CV | Millennium adds put option to old COR Therapeutics convertibles
|
3/14/2002 | CV | Millennium starts tender COR Therapeutics convertibles, considering adding put option
|
12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
12/6/2001 | CV | S&P rates new Photronics convertibles B
|
12/6/2001 | CV | Market Commentary: Convertible market slips on thwarted rally in stocks; new issues mixed
|